{"classes":[{"categories":[{"measurements":[{"comment":"The 95% upper confidence limit was not reached.","groupId":"OG000","lowerLimit":"8","upperLimit":"NA","value":"25.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest objective status is first noted to be either a CR or PR to the earliest date progression is documented. MR for Waldenstrom lymphoma will not be included as a response. Median duration of response and the confidence interval for the median duration will be computed.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m2 IV on day 1\n\n\\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\n\n\\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\n\n\\> Dexamethasone 40 mg PO on days 1, 8, 15, 22","id":"OG000","title":"Treatment"}],"paramType":"MEDIAN","populationDescription":"Thirteen patients achieved a CR or a PR and are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 3 years from registration","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}